Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 9/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.32 |
| ▸ | KRAS | P01116 | 1/20 | 0.31 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29420649 | 0.80 | MAPKAPK2 (0.41) | MAPKAPK2PDE10A | |
| SCHEMBL21331319 | 0.80 | MAPKAPK2 (0.41) | MAPKAPK2PDE10A | |
| SCHEMBL21931895 | 0.79 | GPR119 (0.37) | PIM1PIM3PIM2 | |
| SCHEMBL31416583 | 0.77 | MAPKAPK2 (0.40) | PIM1PIM3PIM2MAPKAPK2GRM5 | |
| SCHEMBL30045747 | 0.76 | MAPKAPK2 (0.44) | MAPKAPK2ALDH1A1 | |
| SCHEMBL21999413 | 0.72 | MAPKAPK2 (0.38) | MAPKAPK2GRM5 | |
| SCHEMBL2596088 | 0.72 | ABL1 (0.38) | PDE10A | |
| SCHEMBL1304590 | 0.71 | PDE10A (0.43) | PDE10A | |
| Hydrochloric Acid SCHEMBL21931904 | 0.71 | MAPKAPK2 (0.37) | MAPKAPK2GRM5 | |
| SCHEMBL25255898 | 0.70 | SCD5 (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11926616-B2 | Aminopyrazine diol compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2024-03-12 | — | — | US | disclosed |
| US-20220411383-A1 | AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-20220213065-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| EP-3762368-B1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-Y INHIBITORS | INCYTE CORP (US) | 2022-01-26 | — | — | EP | disclosed |
| US-11161838-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2021-11-02 | — | — | US | disclosed |
| US-11046658-B2 | Aminopyrazine derivatives as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200339542-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2020-10-29 | — | — | US | disclosed |
| WO-2020102150-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200148671-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161838-B2 | Heterocyclic derivatives as PI3K inhibitors | PIK3CD, PIK3R5, PIK3CG | PIM1 556/4885PIM3 519/4885PIM2 551/4885 |
| US-11046658-B2 | Aminopyrazine derivatives as PI3K-γ inhibitors | PIK3R5, PIK3CD, PIK3CG | PIM1 655/4885PIM3 704/4885PIM2 479/4885 |
| US-20220213065-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | PIK3CD, PIK3R5, PIK3CG | PIM1 770/4885PIM3 765/4885PIM2 559/4885 |
| US-20200148671-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | PIK3CD, PIK3R5, PIK3CG | PIM1 556/4885PIM3 519/4885PIM2 551/4885 |
| US-11926616-B2 | Aminopyrazine diol compounds as PI3K-γ inhibitors | PIK3CD, PIK3R5, PIK3CG | PIM1 737/4885PIM3 784/4885PIM2 571/4885 |
| US-20220411383-A1 | AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS | PIK3R5, PIK3CD, PIK3CG | PIM1 769/4885PIM3 728/4885PIM2 527/4885 |
| US-20200339542-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | PIK3CD, PIK3R5, PIK3CG | PIM1 770/4885PIM3 765/4885PIM2 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.